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THE HATCH-WAXMAN ACT’S SIDE EFFECTS: PRECAUTIONS FOR
BIOSIMILARS
by Anna B. Laakmann ........................................................................... 917
The Drug Price Competition and Patent Term Restoration Act of 1984
(generally known as the Hatch-Waxman Act, or “Hatch-Waxman”) was
designed to expedite regulatory approval of generic drugs while simultaneously
preserving incentives for innovators to invest in the research and development
of new drugs. While Hatch-Waxman has undoubtedly achieved its aim of
creating a robust generic pharmaceuticals market, it has also produced several
unanticipated consequences. Its changes to the federal regulatory scheme have
yielded convoluted products liability rules, upsetting the conventional notion
that the seller of a defective product is liable for harm caused by its intended
use. In addition, its modifications to patent law have had the perverse effects of
propagating patents of questionable value and encouraging potentially anticompetitive agreements between generic and brand name manufacturers.
Hatch-Waxman’s emergent repercussions are particularly salient in light of
the recent passage of the Biologics Price Competition and Innovation Act
(BPCIA). The BPCIA, enacted as part of the Patient Protection and Affordable
Care Act of 2010, crafted a compromise between pioneer and follow-on
biologics manufacturers patterned after Hatch-Waxman’s regulatory scheme
for pharmaceuticals. This Article reviews Hatch-Waxman unintended effects,
and suggests that they should serve as precautionary guideposts for
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implementation of the BPCIA. The FDA and lawmakers should heed these
potential pitfalls and proactively confront unavoidable tradeoffs between
safety, cost, and access to therapeutic biologics.

REDEFINING MEDICAL NECESSITY: A CONSUMER-DRIVEN SOLUTION
TO THE U.S. HEALTH CARE CRISIS
by Ryan Abbott & Carl Stevens ............................................................. 943
The American health care system is plagued by high costs and poor public
health outcomes, due in part to the overuse of costly diagnostic tests and
treatments. In 2009, the Institute of Medicine estimated that unnecessary care
wastes $750 billion, equivalent to about 30 percent of health care spending.
Moreover, overtreatment can directly harm patients as a result of surgical
complications, drug toxicity, and hospital-acquired infections.
Yet while the problem of medical waste has long been recognized,
solving the problem has proven elusive. In part, this difficulty is due to
perverse economic incentives for physicians and hospitals, which still
primarily receive reimbursement on a fee-for-service basis. Providers are
financially motivated under this system to generate a higher volume of
invasive procedures independent of their likely benefits. Patients generally
lack the information needed to decline unnecessary services, even when they
wish to actively share in medical decision-making, and a strong cultural bias
pushes both patients and physicians to “do more,” even when evidence
suggests that doing more may result in harm. In the 1990s, managed health
care organizations attempted to rein in health care waste by stringently
reviewing and prospectively denying payment for unnecessary tests and
treatments, but that experiment was a political failure. Similarly, attempts to
reduce overuse by shifting financial risk directly onto providers through
capitated payment mechanisms have had limited success. The ability of these
mechanisms to limit waste is compromised by the real or perceived incentive
to also reduce spending on appropriate care.
We propose a new conception of medical necessity that will reduce
inappropriate care by allowing informed consumers to actively participate in
decisions about their medical care. Where evidence-based guidelines are
available, medical necessity should be determined on the basis of an
objective, multi-level Matrix of Appropriateness rather than the subjective
binary decision of an insurance company’s medical reviewer. Such Matrices
have already been created by systematically combining published evidence
with expert judgment to create clinically detailed, evidence-based, multilevel medical necessity ratings for elective procedures based on individual
patient characteristics. In our proposed system, if a patient desires a service
proposed by a physician under clinical circumstances that receive low
medical necessity ratings, the third-party payer would offer to cover the
service but at a sliding co-payment scale imposing greater patient cost
sharing based on the service’s appropriateness. This system would preserve
patient choice while discouraging the overuse of costly treatments that
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provide little marginal value, reducing medical waste and improving the
overall value of medical care.
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